Literature DB >> 8182007

Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers.

P R Gangadharam1, S Kailasam, S Srinivasan, D L Wise.   

Abstract

In previous studies we showed that a single implant of polylactic-co-glycolic acid (PLGA) polymer as a film containing isoniazid ensured sustained release of the drug for up to 4 weeks. These studies have been extended to PLGA polymer as a rod which is retrievable. Both types of implant gave therapeutically active levels of free isoniazid in liver and urine for prolonged periods. We assessed the in vivo chemotherapeutic efficacy of the rod implant against heavy infections of virulent Mycobacterium tuberculosis in C57Bl/6 mice. The chemotherapeutic data essentially confirmed the bioavailability data. In one chemotherapeutic study, one (7%) out of 15 mice which received the isoniazid polymer implant died within 30 days of bacterial challenge, while none of those receiving daily oral treatment died. In contrast, 14 (93%) of the 15 control mice died during the same period. In a second study similar results were obtained.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182007     DOI: 10.1093/jac/33.2.265

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.

Authors:  M Dutt; G K Khuller
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  PLGA Carriers for Controlled Release of Levofloxacin in Anti-Tuberculosis Therapy.

Authors:  Evgeny N Antonov; Sofya N Andreevskaya; Irina V Bocharova; Sergei E Bogorodsky; Larisa I Krotova; Elena E Larionova; Alexandra O Mariyanats; Gennady V Mishakov; Tatiana G Smirnova; Larisa N Chernousova; Vladimir K Popov
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525

3.  Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Authors:  Salmaan Keshavjee; Farhana Amanullah; Adithya Cattamanchi; Richard Chaisson; Karen M Dobos; Gregory J Fox; Howard E Gendelman; Richard Gordon; Anneke Hesseling; Hoi Le Van; Beate Kampmann; Bavesh Kana; Gopal Khuller; David M Lewinsohn; Deborah A Lewinsohn; Philiana Ling Lin; Lenette Lin Lu; Gary Maartens; Andrew Owen; Marina Protopopova; Jyothi Rengarajan; Eric Rubin; Padmini Salgame; Erwin Schurr; James A Seddon; Susan Swindells; David M Tobin; Zarir Udwadia; Gerhard Walzl; Sudha Srinivasan; Roxana Rustomjee; Payam Nahid
Journal:  Am J Respir Crit Care Med       Date:  2019-03-01       Impact factor: 21.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.